Recent research has raised concerns about weight loss injections like semaglutide (sold as Ozempic and Wegovy), revealing a potential link to a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). People with diabetes on semaglutide were four times more likely to develop NAION, and those who were overweight or obese faced a sevenfold higher risk compared to other weight loss medications. The condition, often termed an 'eye stroke', can cause sudden vision loss ...